An Open-Label Randomized Active-Controlled
Phase II Clinical Study to Assess the Efficacy & Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (PROFECTA-II/GOG-3044)
Prof Ahmed Badheeb
Speaker